Combining Everolimus with standard therapy for advanced breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial investigates the efficacy and safety of Everolimus when combined with standard first-line endocrine therapy for patients with HR+/HER2- SNF1 subtype advanced breast cancer. The study involves a randomized, controlled, open-label design, enrolling 584 patients who have undergone surgery and are classified into subtypes using advanced digital pathology techniques. Participants will be assigned to either the treatment group receiving Everolimus plus endocrine therapy or a control group receiving only standard endocrine therapy, with treatment continuing until disease progression or other specified criteria are met.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients need to meet all of the following conditions

  * Patients must be ≥18 and ≤ 75 years of age;
  * Pathologically confirmed breast cancer is HR+/HER2- breast cancer (IHC ER \>10%, or/and PR\>10%, HER 0 OR +, if HER2++, FISH negative);
  * SNF1 subtype definition: SNF1 subtype confirmed by digital pathology of H\&E sections;
  * Locally advanced breast cancer (radical local therapy is not possible) or metastatic breast cancer (without using adjuvant CDK4/6 inhibitors in the past, or one year after adjuvant CDK4/6 inhibitor therapy has ended);
  * No prior therapy (chemotherapy, targeted therapy, etc.) for advanced or metastatic breast cancer;
  * Patients with at least one measurable lesion that has not previously received radiation therapy and can be evaluated repeatedly according to RECIST 1.1;
  * The functions of the main organs are basically normal, and the following conditions are met:

    1. Blood routine examination standards should meet: HB≥90g/L (no blood transfusion within 14 days); ANC≥1.5×109/L; PLT≥75×109/L;
    2. Biochemical examination shall meet the following standards: TBIL≤1.5×ULN (upper limit of normal value); ALT and AST≤3 x ULN; In case of liver metastasis, ALT and AST≤5×ULN; Serum Cr ≤1.5×ULN, endogenous creatinine clearance \> 50ml/min (Cockcroft-Gault formula);
  * ECOG performance status 0 or 1; The expected survival is more than 3 months;
  * Fertile female is required to use a medically approved contraceptive during study treatment and for at least 3 months after the last use of the study drug;
  * Patients voluntarily join the study, sign the informed consent, have good compliance, and cooperate with follow-up.

Exclusion Criteria:

* Patients with any of the following conditions were excluded from the study

  * Patients with central nervous system metastasis out of control (symptoms need to use glucocorticoids or mannitol).
  * A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the last 6 months, or ventricular arrhythmia;
  * Radiotherapy, chemotherapy, surgery, other targeted therapy and immunotherapy for advanced HR+/HER2- breast cancer within 4 weeks prior to first administration of drugs used in this study.
  * Pregnant or lactating patients;
  * Other malignancies within the previous 3 years, excluding cured skin basal cell carcinoma and cervical carcinoma in situ;
  * Significant comorbid medical conditions, including mental illnesses that the investigator or sponsor believes would adversely affect the patient's participation in the study;
  * Allergic physique, or known allergic history of the drug components of this program; Or allergic to other monoclonal antibodies;
  * The investigator does not consider the patient suitable for participation in any other circumstances of the study.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Zhimin Shao, MD,PhD — Fudan University
• Study coordinator: Zhimin Shao, MD, PhD
• Email: zhimingshao@yahoo.com
• Phone: +86-021-64175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

• Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment

  This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.

  Recruiting at 15 sites Phase 3 Women's Cancer Study Group GmbH · Anderlecht and 15 other locations · NCT07281833

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• Testing new antibody drugs in advanced breast cancer patients who have used similar treatments before

  This study is testing new antibody drugs to see if they can help advanced breast cancer patients who have already tried similar treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06649331

• Understanding the in-home hospice experience for breast cancer patients

  This study looks at how to improve hospice care for breast cancer patients at home by checking in with them and their caregivers through telehealth to see what works best.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06507930

• Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

  This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT06263543

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.